CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): PATHOGENESIS, CLINICAL COURSE AND MODERN MANAGEMENT

Abdusamiyeva Nargiza Qudratovna
nargizabdusamiyeva@gmail.com
nargiza_abdusamiyeva@tues.uz
Tangriyeva Mohinur Hazratqul qizi
mohinurtangriyeva2005@gmail.com
Odiljonov Ozodbek Odiljon o‘g‘li
odiljonnorkulov0@gmail.com
https://orcid.org/0009-0000-4932-4354

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a progressive inflammatory lung disease characterized by persistent airflow limitation that is not fully reversible. It is a leading cause of morbidity and mortality worldwide, primarily associated with long-term exposure to tobacco smoke and environmental pollutants. This study analyzes the epidemiology, pathophysiology, clinical presentation, diagnostic criteria, complications, and modern management strategies of COPD using the IMRAD structure and current evidence-based guidelines.

Keywords

Chronic Obstructive Pulmonary Disease, COPD, Airflow Limitation, Emphysema, Chronic Bronchitis, Smoking, Spirometry, FEV1, Inflammation, Bronchodilators

Introduction

Chronic Obstructive Pulmonary Disease affects more than 390 million people globally and is among the top three causes of death worldwide. COPD is characterized by chronic inflammation of the airways, destruction of lung parenchyma, and narrowing of small airways, leading to progressive airflow obstruction.

The primary risk factors include:

- Cigarette smoking (most significant factor)
- Air pollution
- Occupational dust and chemicals
- Biomass fuel exposure
- Genetic predisposition (e.g., alpha-1 antitrypsin deficiency)

COPD includes two main pathological components:

1. Chronic bronchitis
2. Emphysema

The aim of this study is to evaluate the pathophysiology, clinical manifestations, diagnostic approaches, and modern therapeutic strategies for COPD.

Methods

This study is based on review of international guidelines (GOLD Report 2024), WHO reports, and randomized controlled trials published between 2015–2024.

Inclusion criteria:

- Adults ≥40 years
- Diagnosed COPD confirmed by spirometry
- FEV1/FVC ratio <0.70

Exclusion criteria:

- Asthma
- Acute respiratory infections
- Pediatric respiratory diseases

Key parameters analyzed:

- FEV1 decline
- Exacerbation frequency
- Hospitalization rate
- Mortality outcomes

Results

1. Pathophysiology

COPD progression involves chronic airway inflammation and structural changes:

Step 1: Chronic Inflammatory Response

Exposure to harmful particles activates inflammatory cells (neutrophils, macrophages).

Step 2: Airway Narrowing

Thickening of bronchial walls and mucus hypersecretion.

Step 3: Alveolar Destruction (Emphysema)

Loss of elastic recoil reduces airflow during expiration.

Figure 1. Structural Changes in COPD (Description)

The illustration shows narrowed bronchi with mucus accumulation, inflammatory cell infiltration, and enlarged alveolar spaces due to destruction of alveolar walls in emphysema.

2. Clinical Manifestations

Common symptoms include:

- Chronic cough
- Sputum production
- Dyspnea (especially on exertion)
- Wheezing
- Chest tightness

Advanced disease may lead to:

- Cyanosis
- Weight loss
- Barrel chest
- Use of accessory respiratory muscles

Figure 2. Air Trapping in Emphysema (Description)

The diagram demonstrates hyperinflated lungs caused by air trapping during expiration due to loss of alveolar elasticity.

3. Diagnosis

The gold standard diagnostic test is **spirometry**.

Diagnostic criteria:

- Post-bronchodilator FEV1/FVC < 0.70

Severity is graded based on FEV1 percentage predicted:

- GOLD 1 (Mild): ≥80%
- GOLD 2 (Moderate): 50–79%
- GOLD 3 (Severe): 30–49%
- GOLD 4 (Very Severe): <30%

Additional tests:

- Chest X-ray
- CT scan
- Arterial blood gases (advanced cases)

4. Complications

- Acute exacerbations
- Pulmonary hypertension
- Cor pulmonale
- Respiratory failure
- Increased cardiovascular risk

Figure 3. Progression to Cor Pulmonale (Description)
The illustration shows how chronic hypoxia leads to pulmonary vasoconstriction, increased pulmonary artery pressure, and right ventricular hypertrophy.

5. Treatment Strategies

Lifestyle and Preventive Measures

- Smoking cessation (most effective intervention)
- Vaccination (influenza, pneumococcal)
- Pulmonary rehabilitation
- Oxygen therapy (in severe hypoxemia)

Pharmacological Therapy

1. Short-acting bronchodilators (SABA, SAMA)
   - Symptom relief
2. Long-acting bronchodilators (LABA, LAMA)
   - Improve lung function
   - Reduce exacerbations
3. Inhaled corticosteroids (ICS)
   - For patients with frequent exacerbations
4. Combination therapy (LABA + LAMA ± ICS)
   - Most effective in advanced disease

6. Management of Exacerbations

Acute exacerbations are treated with:

- Short-acting bronchodilators
- Systemic corticosteroids
- Antibiotics (if bacterial infection suspected)
- Non-invasive ventilation (in severe cases)

Discussion

COPD is a preventable and treatable disease, yet remains underdiagnosed in early stages. The inflammatory process leads to irreversible structural lung damage over time.

Smoking cessation significantly slows disease progression. Early pharmacological therapy improves quality of life and reduces hospital admissions.

Pulmonary rehabilitation has shown strong evidence in improving exercise tolerance and reducing dyspnea.

Emerging therapies are focused on:

- Anti-inflammatory biologics
- Regenerative lung medicine
- Personalized inhaler therapy

Public health policies must address air pollution and tobacco control to reduce global COPD burden.

Conclusion

Chronic Obstructive Pulmonary Disease is a progressive internal disease characterized by persistent airflow limitation and systemic complications. Early detection, smoking cessation, pharmacological management, and pulmonary rehabilitation significantly improve patient outcomes. Comprehensive prevention strategies are essential to reduce global morbidity and mortality.

References

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2024). Global Strategy for Prevention, Diagnosis and Management of COPD.
2. World Health Organization. (2023). Chronic Respiratory Diseases Report.
3. Vestbo J, et al. (2013). Global strategy for diagnosis, management, and prevention of COPD. American Journal of Respiratory and Critical Care Medicine.
4. Calverley PMA, et al. (2007). Salmeterol and fluticasone in COPD. New England Journal of Medicine.
5. Wedzicha JA, et al. (2016). Extrafine beclomethasone/formoterol in COPD. The Lancet.
6. Barnes PJ. (2016). Inflammatory mechanisms in COPD. Journal of Clinical Investigation.
7. Celli BR, et al. (2015). Natural history of COPD. European Respiratory Journal.